Pasithea Therapeutics Corp. KTTA 深 滬
等待開盤 09-24 09:30:00 美东时间
0.5127
-0.001
-0.27%
華盛通- 最 高0.52
- 今 開0.508
- 成交量 11.40万股
- 最 低 0.5017
- 昨 收 0.5141
- 總市值 1713.16万
- 52周最高 2.06
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 0.281
- 委 比 -42.86%
- 總股本 3341.44万
- 歷史最高 170.00
- 量 比 0.55
- 振 幅 3.56%
- 歷史最低 0.281
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1)-associated neurofibromas, tod...
09-14 19:08
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Corp. will present initial clinical data from its Phase 1/1b trial of PAS-004 for neurofibromatosis type 1 (NF1) at the 2026 European Neurofibromatosis Conference in Vienna, Austria. The data on cutaneous neurofibromas (CN) will be presented orally by Rebecca Brown, MD, while plexiform neurofibromas (PN) data will be showcased in a poster by Tiago Reis Marques, CEO of Pasithea. The conference will take place November 12–14, ...
09-14 11:00
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Pasithea Therapeutics Corp. will participate in two investor conferences in September 2026: the 12th Annual Cantor Global Healthcare Conference (September 9-11) and the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16). Management will hold one-on-one investor meetings at Cantor Global and present at H.C. Wainwright on September 14, 2026, at 2:30 PM ET. The Company is developing PAS-004, a next-generation macrocyclic oral...
09-03 20:05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Pasithea Therapeutics Corp. announced that an abstract detailing the Phase 1 dose-escalation study of PAS-004, a next-generation macrocyclic MEK inhibitor, in patients with MAPK pathway-driven advanced solid tumors, has been accepted for poster presentation at the ESMO Congress 2026. The presentation will occur on Friday, October 23, 2026, and the full abstract will be published on the ESMO website under the congress' embargo policy. PAS-004 is b...
07-21 11:00
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Pasithea Therapeutics Corp. announced that its management will participate in the Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The event, hosted by B. Riley Securities, focuses on neuropsychiatry, neurodegeneration, neuromuscular diseases, ophthalmology, and neuroimmunology. Pasithea will engage with investors and industry participants to discuss PAS-004, a next-generation macrocyclic MEK inhibitor for treating chronic diseases like ...
07-08 11:02
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type ...
06-30 19:04
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Pasithea Therapeutics Corp. announced interim results for PAS-004, a next-generation MEK inhibitor, showing favorable safety and tolerability in a Phase 1 trial. The drug demonstrated long-term chronic dosing potential with no Grade 3 or higher treatment-related adverse events, including no cardiac or retinal toxicities. PAS-004 achieved disease stabilization in heavily pre-treated patients, including those with BRAF mutations who previously fail...
06-30 11:00
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.
06-16 23:36
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics Corp. has amended its Phase 1/1b clinical trial protocol for PAS-004 in NF1 patients with plexiform neurofibromas (PN). The updates include adding two higher dose levels (24mg and 32mg), allowing backfilling of completed dose cohorts, and extending the treatment period to 18 months. Additional MRI scans and detailed tumor measurements will be included. The company has completed enrollment and dosing for initial cohorts (4mg,...
06-16 11:00
